Catello Somma, Partner at Seroba on Working in VC, Non-Linear Biotech Careers, and advice for those seeking VC careers

Catello Somma, Partner at Seroba on Working in VC, Non-Linear Biotech Careers, and advice for those seeking VC careers

In this episode, I talked with Catello Somma, Partner at Seroba, to learn about his nonlinear journey from academia and biopharma into venture capital—and the realities behind building funds, backing biotech founders, and surviving industry downturns.

Catello shares the turning points that shaped his career: walking away from his PhD to get closer to patients, breaking into VC after years in biotech operations, and the hard decision to leave a fund when partnership opportunities weren’t on the table. He also gives an insider’s view on what people get wrong about venture capital—the pressure of fundraising cycles, the competition for partnership seats, and why the job is far from the traditional perception of “writing checks from a couch.”

And to round things off, he takes on some quick-fire questions, from his daily coffee intake to the advice he wishes he’d heard earlier in his career.

(Find out more in the episode.)

Here’s What You’re In For

  • The skills biotech professionals often lack when they first enter VC
  • The hard truth about career progression in VC—why few ever make partner
  • How the biotech funding downturn is reshaping investor behavior


Timestamps

1:45 – Leaving academia, dropping a PhD, and first steps into industry

4:02 – Pros and cons of entering VC from biotech vs finance-only backgrounds

8:13 – What differentiates Seroba: flat structure, collegiality, and no egos

10:02 – How the biotech recession and closed IPO window reshaped strategies

13:11 – The biggest misconceptions about venture capital work

16:14 – The insecurity of VC careers: five-year fund cycles and job risk

17:29 – Hard lessons: breaking into VC and walking away when promotion wasn’t possible

19:35 – Quick-fire round: coffee habits, books, family life, funniest dinner with Kevin


About Catello

Catello Somma is a Partner at ROA Ventures, where he invests in early-stage life science companies across Europe and North America. His path into venture wasn’t straightforward: after leaving a PhD program to get closer to patients, he built his career in CROs and biotech operations, later completing an MBA to bridge the gap between science and finance.

Before joining Seroba, Catello worked on both sides of the biotech ecosystem, from building operational teams to structuring deals. Currently, he focuses on supporting founders through the toughest parts of the journey: scaling companies, navigating funding cycles, and preparing for exits. Known for his pragmatic approach and emphasis on culture, Catello brings a long-term mindset to venture—balancing the pressures of short-term market shifts with the resilience needed to build enduring biotech businesses.

Connect with Catello:



About me

My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.

Connect with me:




Opinions and comments expressed by the guest do not represent the company and are fully their own.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(74)

Eliot Forster, CEO at Levicept on 30 Years in Pharma, Running a Six-Person Biotech, and the Future of European Drug Development

Eliot Forster, CEO at Levicept on 30 Years in Pharma, Running a Six-Person Biotech, and the Future of European Drug Development

In this episode, I talked with Eliot Forster, CEO of Levicept, a neurophysiologist-turned biotech veteran with 30+ years of experience across Big Pharma and a series of CEO roles. We get into clinical...

7 Sep 45min

Michael Zaiac, Medical Affairs Lead for Oncology at Daiichi Sankyo on 30 Years of Hiring Lessons, The ADC Wave, and Building Teams in a Fast-Moving Pipeline

Michael Zaiac, Medical Affairs Lead for Oncology at Daiichi Sankyo on 30 Years of Hiring Lessons, The ADC Wave, and Building Teams in a Fast-Moving Pipeline

In this episode, I talked with Michael Zaiac, Medical Affairs Lead for Oncology across Europe and Canada at Daiichi Sankyo — a trained surgical oncologist who walked away from the operating table, mov...

24 Aug 39min

Juho Jalkanen, CEO at Faron Pharmaceuticals on From Surgeon to CEO, Rethinking Boards, and Fighting for the Right Science

Juho Jalkanen, CEO at Faron Pharmaceuticals on From Surgeon to CEO, Rethinking Boards, and Fighting for the Right Science

In this episode, I talked with Dr. Juho Jalkanen, CEO of Faron Pharmaceuticals — a publicly listed Finnish biotech building novel immunotherapies for blood cancers. Juho's path is unlike most you'll h...

10 Aug 37min

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

In this episode, I talked with Dr. Tobias Kampfenkel, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine. Tobias spent nearly a decade at Janssen building ...

15 Juni 39min

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

In this episode, I talked with Sofia Heigis, Chief Executive Officer of OncoPeptides, about a career path that did not start where she expected. Sofia originally wanted to move into clinical operation...

31 Maj 38min

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

In this episode, I talked with Jens Lindberg, CEO of Medivir AB, a Swedish biotech developing innovative therapies in liver cancer and rare disease. Jens brings over 30 years of late-stage development...

18 Maj 33min

Hubert Truebel,  Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

Hubert Truebel, Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

In this episode, I talked with Hubert Truebel, Managing Director at DEBRA Research, to discover a career that wasn’t built traditionally—but through creating opportunities where none formally existed....

4 Maj 28min

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

In this episode, I talked with Sampreet Ramachandra, Head of the Hematology Business Unit at Novartis Germany, about what it really takes to lead high-stakes launches — and what leadership looks like ...

30 Mars 42min

Populärt inom Business & ekonomi

framgangspodden
varvet
rss-jossan-nina
rss-borsens-finest
24fragor
svd-tech-brief
avanzapodden
badfluence
uppgang-och-fall
lastbilspodden
fill-or-kill
rss-inga-dumma-fragor-om-pengar
rss-kort-lang-analyspodden-fran-di
tabberaset
rss-dagen-med-di
bathina-en-podcast
rikatillsammans-om-privatekonomi-rikedom-i-livet
kapitalet-en-podd-om-ekonomi
affarsvarlden
borsmorgon